AU2001257444A1 - Methods and compositions for enhancing cellular function through protection of tissue components - Google Patents

Methods and compositions for enhancing cellular function through protection of tissue components

Info

Publication number
AU2001257444A1
AU2001257444A1 AU2001257444A AU5744401A AU2001257444A1 AU 2001257444 A1 AU2001257444 A1 AU 2001257444A1 AU 2001257444 A AU2001257444 A AU 2001257444A AU 5744401 A AU5744401 A AU 5744401A AU 2001257444 A1 AU2001257444 A1 AU 2001257444A1
Authority
AU
Australia
Prior art keywords
compositions
methods
protection
cellular function
tissue components
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001257444A
Inventor
Xueqing Chen
John Randall Fawcett
William H. Ii. Frey
Robert Gary Thorne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HealthPartners Research Foundation
Original Assignee
HealthPartners Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HealthPartners Research Foundation filed Critical HealthPartners Research Foundation
Publication of AU2001257444A1 publication Critical patent/AU2001257444A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Methods and compositions for increasing the efficacy of an agent that directly or indirectly affects a muscarinic receptor by administering a pyrophosphate analog. Methods and compositions for protecting a pharmacological agent in a formulation, comprising combining the pharmacological agent with at least one pyrophosphate analog. Methods and compositions for increasing the efficacy of a neurologic agent by administering at least one pyrophosphate analog. Methods and compositions for increasing the efficacy of an agent that neither directly nor indirectly affects a muscarinic receptor by administering at least one pyrophosphate analog.
AU2001257444A 2000-05-01 2001-04-30 Methods and compositions for enhancing cellular function through protection of tissue components Abandoned AU2001257444A1 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US20084300P 2000-05-01 2000-05-01
US60200843 2000-05-01
US60/200,843 2000-05-01
US23026300P 2000-09-06 2000-09-06
US60/230,263 2000-09-06
US60230263 2000-09-06
US23302500P 2000-09-15 2000-09-15
US60233025 2000-09-15
US60/233,025 2000-09-15
PCT/US2001/013931 WO2001082932A2 (en) 2000-05-01 2001-04-30 Methods and compositions for enhancing cellular function through protection of tissue components

Publications (1)

Publication Number Publication Date
AU2001257444A1 true AU2001257444A1 (en) 2001-11-12

Family

ID=27394213

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001257444A Abandoned AU2001257444A1 (en) 2000-05-01 2001-04-30 Methods and compositions for enhancing cellular function through protection of tissue components

Country Status (7)

Country Link
US (7) US7084126B1 (en)
EP (1) EP1278525B1 (en)
AT (1) ATE344040T1 (en)
AU (1) AU2001257444A1 (en)
CA (1) CA2429162C (en)
DE (1) DE60124240T2 (en)
WO (1) WO2001082932A2 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6902881B2 (en) 2000-10-13 2005-06-07 President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
US6908732B2 (en) 2000-10-13 2005-06-21 President & Fellows Of Harvard College Compounds and methods for regulating cell differentiation
AU2002249795A1 (en) * 2000-11-10 2002-07-24 The President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
FR2828206B1 (en) * 2001-08-03 2004-09-24 Centre Nat Rech Scient USE OF LYSYL OXIDASE INHIBITORS FOR CELL CULTURE AND TISSUE ENGINEERING
US20140212508A1 (en) * 2001-12-20 2014-07-31 John Wayne Kennedy Copper/zinc superoxide dismutase (sod) formulation for the treatment of traumas including amyotropic lateral sclerosis
AU2003231157C1 (en) * 2002-04-29 2009-02-26 Normoxys, Inc. Inositol pyrophosphates, and methods of use thereof
US20040127409A1 (en) * 2002-11-07 2004-07-01 Milkhaus Laboratory, Inc. Method of treatment of psychological conditions by administration of nerve growth factor
US8367610B2 (en) * 2002-11-07 2013-02-05 Beech Tree Labs, Inc. Method of treating cravings by administration of nerve growth factor
EP1583544A4 (en) * 2002-12-30 2008-10-22 Purdue Research Foundation Method of treatment for central nervous system injury
WO2005030793A2 (en) 2003-09-24 2005-04-07 Millennium Pharmaceuticals, Inc. Antibodies which bind human cxcr3
WO2006004201A1 (en) * 2004-07-01 2006-01-12 Eisai R & D Management Co., Ltd. Nerve reveneration promoter
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US7745423B2 (en) * 2004-07-06 2010-06-29 NormOxys, Inc Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US9216161B2 (en) 2004-08-13 2015-12-22 Healthpartners Research Foundation Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
GB0502250D0 (en) * 2005-02-03 2005-03-09 Ic Vec Ltd Use
CA2601641A1 (en) * 2005-03-18 2006-09-28 Oxyplus, Inc. Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin
US20070032443A1 (en) * 2005-08-02 2007-02-08 Jaeseob Kim Therapy for Alzheimer's disease
WO2007025286A2 (en) 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
WO2007111938A2 (en) * 2006-03-23 2007-10-04 The General Hospital Corporation Inflammation-inhibitory serum factors and uses thereof
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood
EP2152085A4 (en) * 2007-05-01 2012-05-23 Normoxys Inc Erythropoietin complementation or replacement
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
EP2182801A4 (en) * 2007-07-31 2011-04-13 Limerick Biopharma Inc Pyrone analog compositions and methods
BRPI0814876A2 (en) * 2007-07-31 2014-09-30 Limerick Biopharma Inc PHOSPHORILATED PYRONA ANALOGS AND METHODS
US20110091440A1 (en) * 2009-03-27 2011-04-21 Robert Sabin Prophylactic and therapeutic treatment of neuro-degenerative diseases and protein aggregation diseases
WO2010110923A2 (en) * 2009-03-27 2010-09-30 Robert Sabin Prophylactic and therapeutic treatment of alzheimer's disease
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
WO2011011060A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
WO2011119136A1 (en) * 2010-03-26 2011-09-29 Robert Sabin Prophylactic and therapeutic treatment of neuro-degenerative diseases and protein aggregation diseases
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
WO2012174481A1 (en) 2011-06-15 2012-12-20 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
US10279012B2 (en) 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
MX2015015560A (en) 2013-05-15 2016-06-17 Univ Minnesota Adeno-associated virus mediated gene transfer to the central nervous system.
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
JP6517239B2 (en) 2014-04-23 2019-05-22 武田薬品工業株式会社 Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive allosteric modulator activity for the treatment of Alzheimer's disease
EP3160445B1 (en) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
US11389473B2 (en) 2015-01-07 2022-07-19 Tonix Pharmaceuticals Holding Corp. Magnesium-containing oxytocin formulations and methods of use
US9878989B2 (en) 2015-06-26 2018-01-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3366679B1 (en) 2015-10-20 2021-03-24 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3452104A1 (en) 2016-04-15 2019-03-13 The Trustees of The University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
US10471007B2 (en) 2016-12-16 2019-11-12 Jeffrey R Olynyk Sublingual therapeutic solutions and methods
BR112019022212A2 (en) 2017-06-01 2020-05-12 Eli Lilly And Company QUICK ACTION INSULIN COMPOSITIONS
CN111163783A (en) * 2017-08-08 2020-05-15 美国政府卫生与公众服务部 Compositions and methods for inhibiting HIV-1 reverse transcriptase
US11819539B2 (en) 2017-09-22 2023-11-21 The Trustees Of The University Of Pennsylvania Gene therapy for treating Mucopolysaccharidosis type II
SG11202102349PA (en) 2018-09-28 2021-04-29 Karuna Therapeutics Inc Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
US11676198B2 (en) 2019-07-30 2023-06-13 Skipify, Inc. Computer-implemented methods of completing an online transaction that is performed via a user computing device and a merchant website running on a merchant computing device

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023248A (en) * 1984-10-23 1991-06-11 Perstorp Ab Method of treating diabetes with inositol triphosphate
JPS61263902A (en) 1985-05-16 1986-11-21 Rikagaku Kenkyusho Plant blight controlling agent
US5135923A (en) * 1986-04-16 1992-08-04 Perstorp Ab Method of treating cardiovascular diseases
FR2629716B1 (en) * 1988-04-07 1991-07-19 Sanofi Sa PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION BASED ON A DIPHOSPHONIC ACID DERIVATIVE
US5082833A (en) 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
CA2070823C (en) * 1989-12-05 1999-01-12 William H. Ii Frey Neurologic agents for nasal administration to the brain
US5132923A (en) * 1990-02-23 1992-07-21 J.A. King & Company, Inc. System for monitoring storage tanks
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
AU703887B2 (en) * 1995-06-06 1999-04-01 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
US5939395A (en) * 1995-06-07 1999-08-17 Board Of Regents, The University Of Texas System Identification of a potent antioxidant from Aloe barbadensis
CA2225453C (en) * 1995-06-26 2004-12-14 Concat, Ltd. Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy and diagnosis
US6083920A (en) 1995-12-21 2000-07-04 Ayurcore, Inc. Compositions for modulating intracellular inositol trisphosphate concentration
EP1027045A4 (en) * 1997-10-31 2004-12-08 Arch Dev Corp Methods and compositions for regulation of 5-alpha reductase activity
US7618615B2 (en) * 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia

Also Published As

Publication number Publication date
US20060009413A1 (en) 2006-01-12
DE60124240D1 (en) 2006-12-14
US20060009414A1 (en) 2006-01-12
CA2429162C (en) 2010-01-05
US7084126B1 (en) 2006-08-01
US20060014716A1 (en) 2006-01-19
US20060030542A1 (en) 2006-02-09
ATE344040T1 (en) 2006-11-15
US20020028786A1 (en) 2002-03-07
US8772263B2 (en) 2014-07-08
US20110236365A1 (en) 2011-09-29
WO2001082932A3 (en) 2002-07-18
US20050272642A1 (en) 2005-12-08
US7786166B2 (en) 2010-08-31
US8765711B2 (en) 2014-07-01
EP1278525B1 (en) 2006-11-02
DE60124240T2 (en) 2007-06-28
US9072756B2 (en) 2015-07-07
US8771681B2 (en) 2014-07-08
WO2001082932A2 (en) 2001-11-08
EP1278525A2 (en) 2003-01-29
CA2429162A1 (en) 2001-11-08
US7972595B2 (en) 2011-07-05

Similar Documents

Publication Publication Date Title
AU2001257444A1 (en) Methods and compositions for enhancing cellular function through protection of tissue components
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
IL153297A0 (en) Compounds and compositions for delivering active agents
WO2000007979A3 (en) Compounds and compositions for delivering active agents
AU2001236457A1 (en) Compounds and compositions for delivering active agents
MY129356A (en) Electrospun pharmaceutical compositions
WO2006069998A3 (en) Glycopyrrolate in cosmetic preparations
AU2274201A (en) Compounds and compositions for delivering active agents
AU2003240949A1 (en) Active agent delivery systems and methods for protecting and administering active agents
MXPA01008611A (en) Compounds and compositions for delivering active agents.
AU2001284985A1 (en) Compounds and compositions for delivering active agents
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
HK1036970A1 (en) Compounds and compositions for delivering active agents.
WO2003011239A3 (en) Sunscreen composition
IL173785A0 (en) Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents
EP2308479A3 (en) Compounds and compositions for delivering active agents
EP1392328A4 (en) Cancer therapy
WO2002015959A3 (en) Compounds and compositions for delivering active agents
PT1121127E (en) PHARMACEUTICAL COMPOSITIONS ORAIS CONTAINING BUPRENORFIN
WO2001007049A3 (en) Ophthalmic composition comprising ketotifen
AU2001261516A1 (en) Semi-solid delivery vehicle and pharmaceutical compositions
EP1453525A4 (en) Selective targeting of apoptotic cells
ZA986720B (en) Photoresponsive sunscreen compositions
AU2002316200A1 (en) Compound and composition for delivering active agents
WO2003061572A8 (en) Anti-inflammatory formulations